CG ′806, a First-in-Class FLT3/BTK Inhibitor, Exerts Superior Potency against AML Cells Harboring ITD, TKD and Gatekeeper Mutated FLT3 or Wild-Type FLT3

FLT3 is widely accepted as a prime target for acute myeloid leukemia (AML) therapy. However, targeted therapy using current available FLT3 inhibitors only achieved limited clinical efficacy in mono-therapy. Acquired mutations of FLT3, including D835 or “gatekeeper” F691 mutations, have been identified in clinical patients who showed resistance/relapse to the inhibitors. CG’806 is a small molecule multi-kinase inhibitor against FLT3 and BTK kinases that is under development to treat FLT3-driven AML.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research